Replies to post #127810 on Biotech Values

[JJM760]

ARIA and MRK get a standard (10-month) review for ridaforolimus in sarcoma. Not great news for Rida, IMO

Not sure I get what you are trying to say. Did anyone really think Rida was going to get a priority review?